ClinicalTrials.gg
Active, not recruitingNCT06317311RUBY-JUpdated Nov 2, 2026

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

A Phase 2 interventional study of Dostarlimab and Carboplatin in Carcinoma, sponsored by GlaxoSmithKline. Active, not recruiting at 15 sites in Japan. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Updated Nov 2, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing carboplatin in Carcinoma — 1 open to participants now, 5 under way, 3 of them phase 3. Carboplatin · Carcinoma.

Enrollment
11th of 22
41 · median 41
Started
2024
with 1 other
Phase 2
15 of 22
1 open now
Registered
20th of 22
by date

Among the 22 studies testing carboplatin in Carcinoma, this one is the 11th largest by enrollment, is one of 2 that started in 2024, is one of 15 in phase 2, and was the 20th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

1 of the 22 studies testing carboplatin in Carcinoma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing carboplatin in Carcinoma, or all of them as a file.
02

Study summary

The goal of this clinical trial is to understand the effectiveness of dostarlimab and carboplatin-paclitaxel followed by dostarlimab monotherapy in participants with endometrial cancer

03

Conditions studied

  • Carcinoma

Keywords

  • Endometrial cancer
  • Dostarlimab
  • Carboplatin
  • Paclitaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has or cytologically proven endometrial cancer with recurrent or advanced disease.
  2. Participant has molecular subtype of defective mismatch repair/microsatellite instability high (dMMR/MSI-H) or mismatch repair proficient/microsatellite stable (MMRp/MSS) determined.
  3. Participant must have primary Stage III or Stage IV disease or first recurrent endometrial cancer with a low potential for cure by radiation therapy or surgery alone or in combination, and presence of at least one per 1.1 based on Investigator's assessment.
  4. Participant is not pregnant or breastfeeding and agrees to use a highly effective method during the study period if a woman of (WOCBP).
  5. Participant has an Performance status (ECOG PS) of 0 or 1.
  6. Participant has adequate organ function, as assessed by hematologic, renal, hepatic and coagulation parameters.

Exclusion criteria

Exclusion Criteria:

  1. Participant has a concomitant , or participant has a prior non-endometrial invasive malignancy who has been disease-free for \<3 years or who received any active treatment in the last 3 years for that malignancy. Non-melanoma skin cancer is allowed.
  2. Participant has any medical history of interstitial lung disease or pneumonitis.
  3. Participant has cirrhosis or current unstable liver or biliary disease.
  4. Participant has known uncontrolled central nervous system , carcinomatosis meningitis, or both.
  5. Participant has a diagnosis of immunodeficiency.
  6. Participant has received prior therapy with an anti- Programmed death protein 1 (), anti- Programmed death ligand 1 (PD-L1), anti- Programmed death ligand 2 (PD-L2), or anti- Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) agent.
  7. Participant has not recovered adequately from AEs.
  8. Participant has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy, or immunotherapy) within 21 days or \<5 times the half-life of the most recent therapy prior to the first dose of study intervention, whichever is shorter.
  9. Participant has received any within 30 days of the first dose of study intervention. Vaccination against coronavirus disease 2019 (COVID-19) using vaccines that are authorized via the appropriate regulatory mechanisms are not exclusionary.
  10. Participant has positive, or positive.
  11. Participant is known infection.
  12. Participant is currently participating and receiving study intervention or has participated in a study of an agent and received study intervention or used an investigational device within 4 weeks of the first dose of treatment.
  13. Participant with to carboplatin and paclitaxel.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Dostarlimab- Carboplatin-Paclitaxel followed by Dostarlimab Monotherapy

    Biological: Dostarlimab · Drug: Carboplatin · Drug: Paclitaxel

Interventions

  • BiologicalDostarlimab

    Dostarlimab is administered via intravenous (IV) infusion at a dose of 500 milligram (mg) for first 6 cycles (each cycle is of 21 days) followed by 1,000 mg from cycle 7 (each cycle is of 42 days)

  • Carboplatin is administered IV at a dose of Area under the concentration time curve (AUC) 5 milligram\*millilitre/ minute (mg•mL/min) for cycles 1 to 6 (each cycle is of 21 days)

  • Paclitaxel is administered IV at a dose of 175 milligram per meter square (mg/m2) for cycles 1 to 6 (each cycle is of 21 days)

06

What researchers measure

Primary outcomes

  1. Durable response rate for 12 months (DRR12) assessed by Blinded independent central review (BICR)

    DRR12 is defined as the proportion of participants with Complete Response (CR) or Partial Response (PR) lasting greater than or equal to (≥) 12 months, per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

    Time frame: Approximately 18 months

Secondary outcomes

  1. DRR12 per RECIST 1.1, assessed by investigator

    Time frame: Approximately 18 months

  2. Progression-free survival (PFS) per RECIST 1.1, assessed by BICR and investigator

    PFS is defined as the time from the date of first dose to the earlier date of assessment of progression or death by any cause

    Time frame: Up to approximately 3 years

  3. Overall survival (OS)

    OS is defined as time from first dose of study intervention to death from any cause

    Time frame: Up to approximately 3 years

  4. Overall response rate (ORR) per RECIST 1.1 assessed by BICR

    ORR is achieving a best overall response (BOR) of CR or PR. BOR is defined as the best confirmed response \[CR \> PR \> Stable disease (SD) \> Progressive Disease (PD) \> Not evaluable (NE)\] from treatment start date until disease progression, death or initiation of next line of therapy, whichever is earlier

    Time frame: Up to approximately 3 years

  5. ORR per RECIST 1.1 assessed by investigator

    Time frame: Up to approximately 3 years

  6. Disease control rate (DCR) per RECIST 1.1 assessed by BICR

    Achieving a BOR of CR, PR, or SD, defined as the best confirmed response (CR \> PR \> SD) from treatment start date until disease progression, death or initiation of next line of therapy, whichever is earlier

    Time frame: Up to approximately 3 years

  7. DCR per RECIST 1.1 assessed by investigator

    Time frame: Up to approximately 3 years

  8. Duration of response (DOR) per RECIST 1.1 assessed by BICR

    DOR is defined as the time from the date of first documented objective response to the date of first documented PD or death, whichever comes first

    Time frame: Up to approximately 3 years

  9. DOR per RECIST 1.1 assessed by investigator

    Time frame: Up to approximately 3 years

  10. Maximum concentration (Cmax) for dostarlimab

    Time frame: Up to 67 weeks

  11. Minimum concentration (Cmin) for dostarlimab

    Time frame: Up to 67 weeks

  12. Number of participants with adverse events (AEs), Immune-related adverse events (irAEs), and serious adverse events (SAEs) by severity

    Time frame: Up to approximately 3 years

  13. Number of participants AEs, irAEs, and SAEs leading to dose modifications such as dose delay or study intervention discontinuation

    Time frame: Up to approximately 3 years

  14. Number of participants with AEs leading to death

    Time frame: Up to approximately 3 years

07

Study locations

15 sites
  • GSK Investigational Site
    Aichi, 464-8681, Japan
  • GSK Investigational Site
    Fukuoka, 811-1395, Japan
  • GSK Investigational Site
    Fukuoka, 830-0011, Japan
  • GSK Investigational Site
    Gunma, 373-8550, Japan
  • GSK Investigational Site
    Hokkaido, 060-8648, Japan
  • GSK Investigational Site
    Hyōgo, 673-8558, Japan
  • GSK Investigational Site
    Numakunai, 028-3695, Japan
  • GSK Investigational Site
    Okayama, 700-8558, Japan
  • GSK Investigational Site
    Osaka, 541-8567, Japan
  • GSK Investigational Site
    Osaka, 569-8686, Japan
  • GSK Investigational Site
    Saitama, 350-1298, Japan
  • GSK Investigational Site
    Shizuoka, 411-8777, Japan
  • GSK Investigational Site
    Tokyo, 104-0045, Japan
  • GSK Investigational Site
    Tokyo, 135-8550, Japan
  • GSK Investigational Site
    Tokyo, 160-8582, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 83 phase 2 interventional studies under Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 88. This study's planned 31 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Jul 2026 → Dec 2026 and completion Aug 2027 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
Mar 19, 2024
StartActual
May 7, 2024
Primary completionEst.
Dec 14, 2026was Jul 2026
CompletionEst.
Sep 30, 2028was Aug 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites removed
Show 5 removed
  • GSK Investigational Site · Chiba, Japan
  • GSK Investigational Site · Ehime, Japan
  • GSK Investigational Site · Ibaraki, Japan
  • GSK Investigational Site · Kanagawa, Japan
  • GSK Investigational Site · Tochigi, Japan
Nov 2, 2026
Primary completion
Jul 15, 2026→Dec 14, 2026
Nov 2, 2026
Study completion
Aug 31, 2027→Sep 30, 2028
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    5 sites removed
    Show 5 removed
    • GSK Investigational Site · Chiba, Japan
    • GSK Investigational Site · Ehime, Japan
    • GSK Investigational Site · Ibaraki, Japan
    • GSK Investigational Site · Kanagawa, Japan
    • GSK Investigational Site · Tochigi, Japan
    Primary completion Jul 15, 2026→Dec 14, 2026
    Study completion Aug 31, 2027→Sep 30, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06317311
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 19, 2024
Start date
May 7, 2024
Primary completion
Dec 14, 2026 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dostarlimab · Carboplatin · Paclitaxel

Start the discussion